Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Committee flags questions about biomarker and genetic testing bill; members raise insurance and privacy concerns
Summary
Members of the Health Care committee discussed bill H.136 on biomarkers and genetic testing, including potential benefits for diagnosis and treatment, and concerns about insurance use, privacy and impacts on people with autoimmune conditions and long COVID.
The Health Care committee discussed H.136 and the broader topic of biomarkers and genetic testing during its May 9 meeting, exploring both clinical benefits and potential policy risks.
Members said biomarkers could speed diagnosis for conditions such as certain autoimmune disorders, long COVID and hereditary risks, and that clinicians described examples where genetic information might change treatment. At the same…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
